Therapeutic area: Metabolic Disorders

Sibnayal® :

Active substances : potassium citrate and potassium hydrogen carbonate

Dosages :

  • Sibnayal 8 mEq, prolonged-release granules
  • Sibnayal 24 mEq, prolonged-release granules

Conditions of supply and use :

  • Medicinal product subject to medical prescription.

SIBNAYAL® has been approved by EMA in April 30th, 2021.

For more information about Sibnayal® please use the link below:


Advicenne signed partnerships with 3 companies for the commercialisation of Sibnayal® in Europe : FrostPharma AB for the Nordic Region of Europe, TwinPharma for Benelux and ExCEEd Orphan for Central and Eastern Europe.